ACM
Asymmetry Capital Management Portfolio holdings
AUM
$188M
This Quarter Return
-23.69%
1 Year Return
+45.88%
3 Year Return
+300.28%
5 Year Return
+633.15%
10 Year Return
–
AUM
$36.2M
AUM Growth
+$36.2M
(-67%)
Cap. Flow
-$54.3M
Cap. Flow
% of AUM
-150.09%
Top 10 Holdings %
Top 10 Hldgs %
74.48%
Holding
38
New
3
Increased
2
Reduced
18
Closed
15
Top Buys
| 1 |
Inogen
INGN
|
$1.25M |
| 2 |
Equillium
EQ
|
$497K |
| 3 |
Bio-Rad Laboratories Class A
BIO
|
$405K |
| 4 |
Insmed
INSM
|
$171K |
| 5 |
GBT
Global Blood Therapeutics, Inc.
GBT
|
$133K |
Top Sells
| 1 |
Acadia Healthcare
ACHC
|
$6.57M |
| 2 |
Jazz Pharmaceuticals
JAZZ
|
$3.72M |
| 3 |
AnaptysBio
ANAB
|
$3.31M |
| 4 |
Pfizer
PFE
|
$3.01M |
| 5 |
Natera
NTRA
|
$2.98M |
Sector Composition
| 1 | Healthcare | 83.46% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Insmed
INSM
$28.8B
| $4.9M | 13.53% | 373,198 +13,016 | +4% | +$171K |
|
|
GBT
2
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $4.38M | 12.1% | 106,684 +3,235 | +3% | +$133K |
|
3
PTC Therapeutics
PTCT
$3.92B
| $3.8M | 10.5% | 110,794 -62,216 | -36% | -$2.14M |
|
|
PTLA
4
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
| $3.32M | 9.18% | 170,129 -81,752 | -32% | -$1.6M |
|
|
AERI
5
DELISTED
Aerie Pharmaceuticals, Inc.
AERI
| $2.08M | 5.73% | 57,486 -15,484 | -21% | -$559K |
|
6
Incyte
INCY
$16.5B
| $2.01M | 5.55% | 31,588 -17,832 | -36% | -$1.13M |
|
7
Centene
CNC
$14.3B
| $1.87M | 5.16% | 16,189 -8,673 | -35% | -$1M |
|
8
UnitedHealth
UNH
$281B
| $1.72M | 4.74% | 6,884 -8,460 | -55% | -$2.11M |
|
9
Neurocrine Biosciences
NBIX
$13.8B
| $1.47M | 4.06% | 20,571 -2,562 | -11% | -$183K |
|
10
CVS Health
CVS
$92.8B
| $1.42M | 3.93% | 21,739 -14,131 | -39% | -$926K |
|
|
11
Inogen
INGN
$216M
| $1.25M | 3.46% | +10,072 | New | +$1.25M |
|
12
Penumbra
PEN
$10.6B
| $1.22M | 3.37% | 9,966 -3,221 | -24% | -$394K |
|
13
DaVita
DVA
$9.85B
| $1.09M | 3.01% | 21,156 -52,315 | -71% | -$2.69M |
|
14
Amicus Therapeutics
FOLD
$2.34B
| $932K | 2.57% | 97,294 -260,897 | -73% | -$2.5M |
|
|
XLRN
15
DELISTED
Acceleron Pharma Inc.
XLRN
| $808K | 2.23% | 18,564 -21,348 | -53% | -$929K |
|
16
Heron Therapeutics
HRTX
$207M
| $801K | 2.21% | 30,861 -24,986 | -45% | -$649K |
|
|
NCNA
17
NuCana
NCNA
$6.09M
| $624K | 1.72% | 43,047 -44,274 | -51% | -$642K |
|
|
VRAY
18
DELISTED
ViewRay, Inc.
VRAY
| $589K | 1.63% | 96,964 -126,921 | -57% | -$771K |
|
19
Verrica Pharmaceuticals
VRCA
$52.8M
| $512K | 1.41% | 62,882 -14,003 | -18% | -$114K |
|
|
20
Equillium
EQ
$62.2M
| $497K | 1.37% | +60,882 | New | +$497K |
|
|
21
Bio-Rad Laboratories Class A
BIO
$8.06B
| $405K | 1.12% | +1,745 | New | +$405K |
|
|
KDMN
22
DELISTED
Kadmon Holdings, Inc.
KDMN
| $401K | 1.11% | 192,637 -129,988 | -40% | -$271K |
|
23
DURECT Corp
DRRX
$59.6M
| $111K | 0.31% | 228,820 -459,626 | -67% | -$223K |
|
|
24
Acadia Healthcare
ACHC
$2.12B
| – | – | -186,631 | Closed | -$6.57M |
|
|
25
AnaptysBio
ANAB
$569M
| – | – | -33,211 | Closed | -$3.31M |
|